Trial: 201906131

A Phase 1 b trial of CPX-351 Lower Intensity Therapy (LIT) plus Venetoclax as First Line Treatment for Subjects with AML who are Unfit for Intensive Chemotherapy


I (Cancer Control)

Principal Investigator

Uy, Geoffrey

Disease Site

Acute Myeloid Leukemia (AML); Myeloid and Monocytic Leukemia

Learn more about this study at: